FDA Warning Letters to Telehealth Companies Selling Compounded Drugs

The FDA has sent warning letters to telehealth companies selling compounded semaglutide and tirzepatide in rounds dated September 2025, February 2026, and June 2026. These letters name the telehealth platform itself as the party that misbranded the drug. The marketing claims cited come from the company's own website: that a compounded product is the same as an FDA-approved drug, that the product itself is FDA-approved, or that the pharmacy supplying it is FDA-licensed. None of those statements is accurate, and the FDA's own compounding guidance says so directly. For the compounding pharmacy filling prescriptions behind a telehealth company's marketing, a warning letter addressed to that marketing partner creates exposure that reaches the pharmacy's own compliance record.

FDA's Warning Letters to Telehealth Platforms

FDA warning letters issued to FWD Care, Inc. on September 9, 2025, and to Altru Telehealth, LLC on June 8, 2026, describe the same pattern. FWD Care's website told visitors its compounded product shared the same active ingredient as brand-name GLP-1 drugs. Altru Telehealth's letter cites the company's claim that its compounded semaglutide and tirzepatide contained an "FDA approved active ingredient" and that its supplying pharmacies were "FDA approved." The FDA responded to both the same way: compounding facilities, including pharmacies and outsourcing facilities, are not FDA-approved or FDA-licensed entities, and a compounded drug does not become FDA-approved because its active ingredient matches one that is.

The Misbranding Theories Behind the Letters

Each letter rests on the same two provisions of the Federal Food, Drug, and Cosmetic Act: Section 502(a) (21 U.S.C. Section 352(a)), which makes a drug's labeling false or misleading in any particular, and Section 502(bb) (21 U.S.C. Section 352(bb)), the compounding-specific provision reaching false or misleading advertising or promotion of a compounded drug. Introducing a misbranded drug into interstate commerce separately violates Section 301(a) (21 U.S.C. Section 331(a)). The FDA's own guidance to telehealth companies lists the claims that trigger both provisions: branding or imagery suggesting the telehealth company itself compounds the drug, describing a compounded product as a "generic version" of or "the same as" an approved drug, stating or implying FDA approval of the product, claiming the product is "clinically proven" to match an approved drug's results, and representing the supplying pharmacy or outsourcing facility as FDA-approved or FDA-licensed.

Why This Reaches the Dispensing Pharmacy

A warning letter naming the telehealth company does not excuse the pharmacy compounding and shipping the prescription behind it. State boards of pharmacy reviewing the same marketing can ask who is actually making the prescribing and medical-necessity decisions behind a telehealth intake form, and a pharmacy whose name never appears in the letter can still be pulled into that inquiry through its own dispensing records. That exposure falls within the same compounding pharmacy defense framework Health Law Alliance applies across its compounding practice.

The pharmacy's own compliance obligations also keep running on a separate track from the marketing dispute. 503A and 503B status, cGMP for outsourcing facilities, the beyond-use date assigned to each preparation, and USP 797 and USP 800 sterile and hazardous-drug compounding standards are all independently enforceable, regardless of what a telehealth partner's website says. Health Law Alliance's coverage of cGMP expectations for outsourcing facilities, cleanroom certification and recertification timelines, and the Form 483 observations most common at 503A compounding pharmacies addresses that separate compliance layer in more detail.

A telehealth company's marketing claims do not change what a compounded drug legally is: a product the FDA has not approved, reviewed for safety, or evaluated for effectiveness.

Why Early Legal Counsel Is Critical

It is critical that compounding pharmacies and their telehealth partners promptly retain experienced healthcare defense counsel upon receiving a warning letter, a state board inquiry, or any other government request tied to compounded drug marketing. Early legal intervention can protect the pharmacy's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk.

How Health Law Alliance Can Help

Health Law Alliance has represented 2,500+ clients nationwide.

If your pharmacy supplies compounded semaglutide or tirzepatide to a telehealth platform that has received an FDA warning letter, or your own marketing language is drawing similar scrutiny, contact Health Law Alliance's GLP-1 compounding defense attorneys for a free, confidential consultation.